News & Events

• June 15, 2022
  

  View Now | Using Ontologies to Standardize Rare Disease Data Collection presented by Monarch Initiative

  This webinar will provide an overview of biomedical ontologies and demonstrate how they can be used for standardizing and integrating data and downstream analyses. In addition, we will discuss why you should contribute to ontology development efforts and how to do it. The Monarch Initiative is an integrative data and analytic platform connecting phenotypes to......
• May 18, 2022
  

  View Now: Generating Synthetic Longitudinal Data presented by Replica Analytics

  In this webinar, Replica Analytics’ Dr. Khaled El Emam is joined by Director of Data Science Lucy Mosquera to provide a general introduction to synthetic data generation (SDG), explaining what it means, how it works and what technologies are used, as well as an overview of the use cases where synthetic data can provide value......
• March 16, 2022
  

  View Now | AI-powered Real-world Simulations for Faster and Value-based Rare Disease Drug Development

  This presentation will to show how Quinten Health can use a data-integrative, value-based and disease-centric analytic approach to support RDCA-DAP’s mission to accelerate and de-risk trials, while maximizing the real-world value of rare disease products in development.

• November 10, 2021
  

  View Now | RDCA-DAP Professional Webinar Series: RDCA-DAP Data Ingestion and Curation Process

  In this month’s webinar, describes RDCA-DAP’s data management practices and use of ontologies, with an emphasis on how the data ingestion and curation processes increase the value of patients’ data.

• October 27, 2021
  

  View Now | RDCA-DAP Professional Webinar Series: RDCA-DAP Collaboration with Clinerion for Real World Data Solutions

  In this webinar, Clinerion scientists will present an existing rare disease use case showcasing Clinerion predictive modeling efforts and discuss how collaboration with RDCA-DAP will leverage data from both platforms, improving the generalizability of such models. Audience discussion and Q&A will be included.